Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy

NCT06332950 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Extensive-stage Small-cell Lung Cancer

Interventions

DRUG: Adebrelimab, Irinotecan Liposome (II)
DRUG: Adebrelimab, Irinotecan Liposome (II), Famitinib

Sponsor

Baohui Han